*ST Jiyou announced that the company paid 964 million yuan in cash to acquire 50.76% of Jiangsu Huiju Pharmaceutical Co., Ltd. The transaction constituted a major asset restructuring and related transaction, did not constitute a restructuring and listing, did not involve the issuance of shares or raising supporting capital, and would not lead to a change in the company's control. As of the announcement date, the underlying assets have been transferred and registered for industrial and commercial changes, and Huiju Pharmaceutical has become a holding subsidiary of the company and is included in the scope of the consolidated statement. As of October 9, 2026, the company has paid 80% of the transfer amount, or 772 million yuan, and the remaining 20% of the price will be paid according to the terms agreed in the agreement.

*ST Jiyou announced that the company paid 964 million yuan in cash to acquire 50.76% of Jiangsu Huiju Pharmaceutical Co., Ltd. The transaction constituted a major asset restructuring and related transaction, did not constitute a restructuring and listing, did not involve the issuance of shares or raising supporting capital, and would not lead to a change in the company's control. As of the announcement date, the underlying assets have been transferred and registered for industrial and commercial changes, and Huiju Pharmaceutical has become a holding subsidiary of the company and is included in the scope of the consolidated statement. As of October 9, 2026, the company has paid 80% of the transfer amount, or 772 million yuan, and the remaining 20% of the price will be paid according to the terms agreed in the agreement.